Clinical trials: Androgens
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Prostate, Prostate Cancer
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.
- Trial name
- NCT00182052
- Testing
- Rosiglitazone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or…
- Trial name
- Himalayas-1 (NCT07723248)
- Testing
- Rinzimetostat, Darolutamide, Enzalutamide
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- ORIC Pharmaceuticals
Prostate Cancer
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration…
- Trial name
- NCT02918968
- Testing
- Enzalutamide, Flutamide, Androgen deprivation therapy
- Where
- 47 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Astellas Pharma Inc
Metastatic Prostate Cancer (PCa) in ADT, Rehabilitation
Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)
This is a drug-free, single arm, single center, superiority, interventional study aimed at treatment feasibility. The main aim of the current study is to assess feasibility of a tailored exercise program as measured by adherence…
- Trial name
- ReCaP (NCT06238596)
- Testing
- rehabilitation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01120236
- Testing
- Bicalutamide, Cixutumumab, Goserelin Acetate
- Where
- 170 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
This is an open label non-comparative controlled randomized phase II study. The experimental arm is the group receiving ODM-201. The group receiving androgen-deprivation therapy (ADT) is included as an internal control.
- Trial name
- NCT02972060
- Testing
- ODM-201, ADT
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 61 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
BN83495 in Prostate Cancer
The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy
- Trial name
- STX64PC (NCT00790374)
- Testing
- BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3)
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Ipsen
Prostate Cancer
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005044
- Testing
- Casodex, Eulexin, LHRH agonist
- Where
- 261 sites in United States, Canada
- Volunteers
- 1,579 people
- Sponsor
- Radiation Therapy Oncology Group
Polycystic Ovary Syndrome
Sebum Measurement in Newborn to Detect Hyperexposure to Androgens
The source of PCOS is unknown. Our hypothesis is that over exposure to testosterone of the foetus in utero alters the expression of genes thought to be involved in the cause of PCOS.
- Trial name
- NCT04065100
- Testing
- Sebum test
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Homerton University Hospital NHS Foundation Trust
Prostatic Neoplasms
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no…
- Trial name
- NCT07832292
- Testing
- JNJ-101556143
- Where
- 5 sites in United States, China
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Prostate Cancer, Prostatic Neoplasms
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer.
- Trial name
- NCT00878436
- Testing
- Panobinostat, Bicalutamide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- NYU Langone Health
Adenocarcinoma of the Prostate
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
We hypothesize that Stereotactic Body Radiotherapy Boost (SBRT) as a boost to the prostate following whole pelvic intensity modulated radiotherapy (IMRT) can be delivered effectively and safely in a population of men with…
- Trial name
- CCRO025 (NCT02064036)
- Testing
- Stereotactic Radiosurgical Boost, Casodex, Leuprolide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Davis
Polycystic Ovary Syndrome, Insulin Resistance
Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS)
Androgen excess is the cardinal biochemical feature of polycystic ovary syndrome (PCOS). Serum testosterone correlates with insulin resistance in PCOS, however, there is an urgent need to improve our understanding of the…
- Conditions
- Polycystic Ovary Syndrome, Insulin Resistance, Androgen; Hypersecretion, Endocrine System Diseases
- Trial name
- DIMOXIS (NCT05263557)
- Testing
- Dehydroepiandrosterone (DHEA), 11-ketoandrostenedione (11KA4)
- Where
- Ireland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Royal College of Surgeons, Ireland
Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly…
- Trial name
- NCT04989946
- Testing
- Degarelix, pTVG-AR, Nivolumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Wisconsin, Madison
PCOS, NAFLD
Androgens and NAFLD Longitudinal Cohort Study
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time.
- Conditions
- PCOS, NAFLD, NASH
- Trial name
- NCT06124261
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained.
- Trial name
- NCT00215683
- Testing
- Degarelix
- Where
- 34 sites in Belgium, Germany and 5 more
- Volunteers
- 137 people
- Sponsor
- Ferring Pharmaceuticals
Mammographic Density
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.
- Trial name
- NCT03264651
- Testing
- enobosarm
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Havah Therapeutics Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.